In The News

Overseas Inspection Delay Dings Drug and Devicemakers

Modern Healthcare

13 Mar 2020

Bethany Hills spoke to Modern Healthcare about the Food and Drug Administration’s postponement of overseas inspections, which will financially drain drug and devicemakers and may compromise products’ quality.

“The financial impact is not just related to getting a product on the market, it is about the long haul of launching a product,” Bethany said. “The part people really struggle with is if they keep all their sales staff, keep hiring, or hold off. How do you tread water and be ready to go at a moment’s notice without knowing when that moment will come?”

Read the full article.

Close
Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.